Compare Charles River Laboratories Intl. Inc (CRL) vs YieldMax TSLA Option Income Strategy ETF (TSLY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Charles River Laboratories Intl. Inc vs YieldMax TSLA Option Income Strategy ETF — how do they compare? Charles River Laboratories Intl. Inc trades at $232.53 (market cap $11.14B), while YieldMax TSLA Option Income Strategy ETF trades at $27.05. The key difference: Charles River Laboratories Intl. Inc is trading nearer its 52-week high, YieldMax TSLA Option Income Strategy ETF nearer its low. Which is the better fit depends on your goals.
| CRL | TSLY | |
|---|---|---|
Market Cap | $11.14B | — |
Sector | Health | Income / Options Overlay |
52-Week High | $233.60 | $48.25 |
52-Week Low | $145.57 | $26.16 |
Enterprise Value | $14.00B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Charles River Laboratories (CRL) trades at $229.75, down 1.57% on the day, near its consensus price target of $229.80. The stock shows a bullish technical trend with strong moving average signals and support at $225. Fundamentally, CRL has beaten EPS estimates for three consecutive quarters but reported a net loss of $144.34 million in 2025, with negative profit margins. Recent news highlights collaborations in AI and NGS services, supporting growth prospects.
Outlook remains mixed: analyst consensus is strongly bullish with 72% buy ratings and a high target of $260, but profitability challenges and high P/E of 684.85 pose risks. Cash flow stability and strategic partnerships offer upside, while margin pressures and debt levels require monitoring for sustained recovery.
TSLY trades at $26.73, down 2.52% today amid bearish technical signals with moving averages indicating selling pressure. The ETF maintains aggressive weekly dividend distributions, with recent payouts ranging from $0.28 to $0.52 per share. Technical indicators show neutral oscillators but overall bearish momentum, with key support at $26 and resistance at $27.
The high-yield strategy faces capped upside potential from covered call overlays while generating substantial income. Key risks include volatility exposure to underlying TSLA performance and return of capital distributions. June catalysts from Tesla's shareholder meeting represent near-term price drivers for the fund.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Charles River Laboratories Intl. Inc
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →About YieldMax TSLA Option Income Strategy ETF
TSLY is an actively managed ETF that seeks to provide high monthly income by employing a synthetic covered call strategy on Tesla, Inc. (TSLA). It does not own Tesla stock directly; instead, it uses a combination of call and put options to simulate long exposure while simultaneously selling call options to collect premiums. It is designed for income-focused investors who are willing to trade TSLA's potential upside for immediate, aggressive yield.
Read more on TSLY →
